OncoCyte Past Earnings Performance
Past criteria checks 0/6
OncoCyte's earnings have been declining at an average annual rate of -3.9%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 4.2% per year.
Key information
-3.9%
Earnings growth rate
23.0%
EPS growth rate
| Biotechs Industry Growth | 11.5% |
| Revenue growth rate | 4.2% |
| Return on equity | -444.3% |
| Net Margin | -6,150.9% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How OncoCyte makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1 | -44 | 13 | 10 |
| 30 Jun 24 | 1 | -37 | 12 | 10 |
| 31 Mar 24 | 1 | -40 | 13 | 9 |
| 31 Dec 23 | 2 | -26 | 14 | 9 |
| 30 Sep 23 | 1 | -22 | 16 | 8 |
| 30 Jun 23 | 1 | -17 | 18 | 7 |
| 31 Mar 23 | 1 | -11 | 20 | 7 |
| 31 Dec 22 | 1 | -19 | 22 | 7 |
| 30 Sep 22 | -1 | -22 | 14 | 2 |
| 30 Jun 22 | 0 | -34 | 16 | 3 |
| 31 Mar 22 | 1 | -43 | 19 | 3 |
| 31 Dec 21 | 2 | -44 | 20 | 5 |
| 30 Sep 21 | 5 | -35 | 29 | 10 |
| 30 Jun 21 | 4 | -28 | 26 | 10 |
| 31 Mar 21 | 2 | -26 | 23 | 11 |
| 31 Dec 20 | 1 | -30 | 22 | 9 |
| 30 Sep 20 | 1 | -32 | 22 | 10 |
| 30 Jun 20 | 0 | -30 | 20 | 9 |
| 31 Mar 20 | 0 | -26 | 19 | 8 |
| 31 Dec 19 | 0 | -22 | 15 | 7 |
| 30 Sep 19 | 0 | -19 | 13 | 5 |
| 30 Jun 19 | 0 | -17 | 11 | 6 |
| 31 Mar 19 | 0 | -16 | 9 | 6 |
| 31 Dec 18 | 0 | -16 | 9 | 6 |
| 30 Sep 18 | 0 | -15 | 8 | 7 |
| 30 Jun 18 | 0 | -19 | 12 | 7 |
| 31 Mar 18 | 0 | -18 | 11 | 7 |
| 31 Dec 17 | 0 | -19 | 12 | 7 |
| 30 Sep 17 | 0 | -19 | 11 | 7 |
| 30 Jun 17 | 0 | -14 | 7 | 7 |
| 31 Mar 17 | 0 | -13 | 7 | 6 |
| 31 Dec 16 | 0 | -11 | 5 | 6 |
| 30 Sep 16 | 0 | -12 | 6 | 6 |
| 30 Jun 16 | 0 | -11 | 6 | 5 |
| 31 Mar 16 | 0 | -10 | 5 | 5 |
| 31 Dec 15 | 0 | -9 | 4 | 5 |
| 30 Sep 15 | 0 | -7 | 2 | 4 |
| 30 Jun 15 | 0 | -5 | 1 | 4 |
| 31 Mar 15 | 0 | -5 | 1 | 4 |
| 31 Dec 14 | 0 | -5 | 1 | 4 |
Quality Earnings: 0KCC is currently unprofitable.
Growing Profit Margin: 0KCC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0KCC is unprofitable, and losses have increased over the past 5 years at a rate of 3.9% per year.
Accelerating Growth: Unable to compare 0KCC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0KCC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: 0KCC has a negative Return on Equity (-444.28%), as it is currently unprofitable.